Key result
Heart-rate variability biofeedback showed high levels of evidence for clinical benefits in coronary heart disease, pain, and hypertension, moderate in cancer, and poor in diabetes and dementia.
Why the study?
Does heart-rate variability biofeedback improve clinical outcomes in patients with chronic conditions such as CHD, hypertension, diabetes, and cancer?
Comparison
HRV-biofeedback intervention studies across various health conditions
Design
Narrative review
Authors
Loading...
Slow-paced breathing may enhance vagal tone in practice; extends RCT evidence for non-invasive HRV modulation in cardiovascular care.
Does heart-rate variability biofeedback improve clinical outcomes in patients with chronic conditions such as CHD, hypertension, diabetes, and cancer?
Heart-rate variability biofeedback has a high level of evidence for providing clinical benefits in coronary heart disease, hypertension, and pain, though evidence remains poor for diabetes and dementia.
Gitler et al. (2022) conducted a review in Hypertension, diabetes, coronary heart disease, cancer, pain, and dementia. Heart-rate variability biofeedback (HRV-B) was evaluated. Heart-rate variability biofeedback showed high levels of evidence for clinical benefits in coronary heart disease, pain, and hypertension, moderate in cancer, and poor in diabetes and dementia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: